Generic Name and Formulations:
Doxepin HCl 5%; crm.
Indications for ZONALON:
Moderate pruritus associated with atopic dermatitis and lichen simplex chronicus.
Apply thin film to affected area 4 times a day at 3–4 hour intervals for up to 8 days. Do not occlude.
Untreated narrow-angle glaucoma. Urinary retention.
During or within 14 days of MAOIs. Poor metabolizers may have increased effects. For dermatological use only. Avoid eyes. Pregnancy (Cat.B). Nursing mothers: not recommended.
Discontinue MAOIs at least 2 weeks before starting. Alcohol, CNS depressants potentiate sedation. May potentiate drugs metabolized by CYP2D6 (eg, cimetidine, tricyclic antidepressants, SSRIs, phenothiazines, carbamazepine, propafenone, flecainide, encainide, quinidine).
Drowsiness, dry mouth, thirst, headache, fatigue, dizziness, emotional or taste changes, burning/stinging, pruritus or eczema exacerbation, skin dryness or tightening, parethesias, edema.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline